Ginkgo Biloba 6250mg Extract 50:1 - 365 Tablets

Neurodegenerative conditions like anxiety, depression, and Alzheimer's disease can result from prolonged exposure to stress. Herbal supplements like Ginkgo biloba and Curcuma longa (turmeric) are being investigated as a result of the search for natural neuroprotective agents. In order to mitigate streptozotocin-induced neurodegeneration, this study examined the effects of combining ginkgo biloba supplements with Curcuma longa root extract. Twenty-five rats weighing between 90 and 120 grammes were split into five groups of five animals each. Group A was the control group; Group B was the negative control group (STZ alone); and Groups C–E were given extracts orally for 21 days at doses of 50, 100, and 150 mg/kg of Ginkgo biloba supplement and 200, 400, and 500 mg/kg of turmeric root extract. Following daily extract administration, a neurobehavioral test was performed. After 21 days, the animals were sacrificed and blood was extracted via ocular puncture into an EDTA container, and the serum was separated for oxidative biomarker analysis by centrifugation. The brain hippocampus was extracted and homogenized to measure the hippocampus absorbance level. Ginkgo biloba supplement and Curcuma longa root extract, at the doses tested on the Group C-E, significantly decreased p≤0.05 MDA, while GSH and SOD significantly increased p≤0.05 compared to group B. The hippocampus absorbance level increased non-significantly when compared to B. When comparing the test group to group B, there was a notable improvement in spatial memory and cognitive function, as evidenced by the significant decrease in escape latency and the number of errors (p≤0.05) and the significant increase in path efficiency. This study implies that some neurodegenerative diseases in diabetic rats may be lessened by the combined application of Curcuma longa roots and Ginkgo biloba supplements.

PURPOSE: This study aims to explore the effect of Ginkgo biloba extracts (GbE) on the prevention of posterior capsule opacification (PCO). STUDY DESIGN: This study was a double-blinded, placebo-controlled, single-center randomized clinical trial. METHODS: Patients with senile cataracts randomly received GbE supplement capsules at a dose of 200 mg (n = 74) or an identical placebo (n = 70) daily for 6 months after cataract surgery. Patients’ follow-ups were scheduled for up to 3 years after cataract surgery. PCO formation (Pearl/Fibrotic) was graded using slit-lamp examinations. The necessity of a Neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy was evaluated by patients’ complaints of reduced visual acuity imputable to PCO. RESULTS: A total of 144 patients with a mean age of 64.92 ± 7.77 years were studied. The mean Log MAR visual acuity in the placebo group started to decrease at 12 months (P = 0.003) and remained significantly lower than the GbE group throughout 36 months (P = 0.005). At 1-year postsurgery, a significant difference between the two groups of GbE and Placebo was observed regarding pearl PCO score, but obvious fibrotic PCO score differences occurred 3 years after surgery. The Nd: YAG capsulotomy was performed in six eyes (6.1%) for the GbE group and 18 eyes (20.4%) for the placebo group (P = 0.004) 3 years after the cataract surgery. CONCLUSION: Six months of supplementation with GbE was well tolerated and may provide some marginal prevention in the PCO formation. Besides the effect of the GbE in the inhibition of PCO, we also observed a noticeable reduction in the need for Nd: YAG laser capsulotomy.

The aim of this study is to present the formulation of MyExosome®, an innovative, fully organic, and vegan functional food supplement containing orally consumable EPDEN’s (edible plant-derived exosome-like nanoparticles), designed to combat and preventive Alzheimer’s disease and dementia. This formulation is produced using EPDEN’s derived from organic Coffea arabica seeds, organic Ginkgo biloba leaves, and organic Panax ginseng root-rhizomes, all of which are known for their neuroprotective properties. The isolation of these nanoparticles and the formulation of MyExosome® were optimized at the AYE Exocure R&D Center. MyExosome®’s preventive and therapeutic effects against Alzheimer’s have been proven in in-vitro (Alzheimer’s model and microglial cells), in-vivo (Alzheimer’s model rats), and clinical studies conducted by AYE Exocure. Our goal is to enhance the stability, selectivity, sensitivity, and specificity of these nanoparticles, providing an effective support to slow down or prevent the progression of neurodegenerative diseases.

Cardiovascular diseases, among which arterial hypertension (AH) occupies a priority place, are independent risk factors for the development and progression of cognitive disorders. The primary strategy in the prevention of dementia remains the correction of cardiovascular risk factors, as well as the search for additional approaches to prevent the development and progression of cognitive dysfunction with the involvement of neuroprotective and vasoprotective therapy. The objective: to evaluate the effect of a fixed combination (FC) of citicoline and ginkgo biloba (dietary supplement Axonal) on cognitive function indicators in patients with mild cognitive impairment (MCI) syndrome compared to monotherapy with citicoline or ginkgo biloba. Materials and methods. The research studied the dynamics of cognitive indicators in patients with AH, who took an FC of citicoline/ginkgo biloba (dietary supplement Axonal) and monotherapy with citicoline or ginkgo biloba for 90 days. A double-blind study enrolled 70 patients with MCI syndrome; their mean age at enrollment was 65.30 ± 5.54 years. All patients received treatment in accordance with the existing standards/protocols for providing medical care, approved by the Ministry of Health of Ukraine. Cognitive functions were assessed using the Montreal Cognitive Assessment Test (MoCA), Schulte tables, symbol-digit test and Stroop test. Results. Comparative analysis demonstrated the superiority of FC of citicoline/ginkgo biloba over the monotherapy group (citicoline or ginkgo biloba) in a significant increase in the MoCA integral test score by 11.4% (from 23.6 ± 1.5 to 26.3 ± 1.7 points, p < 0.001), restoration of cognitive functions in the domains of “executive skills” (0.33 ± 0.65 vs 0.26 ± 0.68 points, p = 0.03); “attention, counting” (0.09 ± 0.29 vs 0.01 ± 0.52 points, p = 0.01) and “memory, delayed repetition” (1.57 ± 1.51 vs 0.71 ± 1.51 points, p = 0.02) and improving the speed of information processing and concentration of a